National Bank of Canada
VKTX icon

National Bank of Canada’s Viking Therapeutics VKTX Stock Holding History

National Bank of Canada’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,186
Closed -$7.69M – 3238
2025
Q1 		$7.69M Buy
+3,186
New +$101K 0.01% 795

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

National Bank of Canada's VKTX Position: Q1 2026 in Review

National Bank of Canada sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 100 shares — an estimated $3.52K sold.

National Bank of Canada first reported a position in VKTX in Q4 2021 and held it in 11 quarters. The position peaked at $7.72M in Q1 2025. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • National Bank of Canada reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 100 Viking Therapeutics shares in Q1 2026, an estimated $3.52K.
  • National Bank of Canada first reported a position in Viking Therapeutics in Q4 2021 and held it in 11 quarters.
  • National Bank of Canada's Viking Therapeutics position peaked at $7.72M in Q1 2025.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.